Promis Diagnostics, Inc. announced that it has issued 1,337,792 common shares at a price of $14.95 per share for gross proceeds of $19,999,990.40 on January 9, 2020. The transaction included participation from returning investor Genomictree Inc. (KOSDAQ:A228760). Post transaction, the investor holds 8,033,473 shares and its stake in the company increased from 90.57% to 92.01%. The total number of shares issued by the company prior to the transaction is 7,393,181 shares. The company raised the funding through third-party allocation. The transaction has been approved by the board of directors of the investor.